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BACKGROUND AND INTRODUCTION 
 
Despite continued public health efforts to increase human papillomavirus 
(HPV) vaccination among adolescents, initiation of the vaccine remains 
below the level needed to reach the Healthy People 2030 goal of 80% series 
completion by age 13.1 Persistent infection with high-risk HPV types 
(predominantly 16 and 18) causes more than 90% of cervical and anal 
cancers, 70% of oropharyngeal cancers, about 70% of vaginal and vulvar 
cancers, and more than 60% of penile cancers.2,3  In the U.S. from 2012-
2015, 44,000 HPV-related cancers were reported (25,000 among women 
and 19,000 among men). The most common HPV-related cancers in the 
U.S. include oropharyngeal (19,000) and cervical (12,015).4-6  Infection with 
HPV types 6 and 11 is associated with the development of genital warts that 
cause significant morbidity in both men and women.7,8 In 2018, HPV 
vaccination rates among Texas youth fell below the U.S. rates as did rates 
of tetanus, diphtheria, and acellular pertussis (Tdap): 83.4% in Texas 
compared with 88.9% in the U.S. The effectiveness of HPV vaccine is 
acknowledged by its recognition as a Healthcare Effectiveness Data and 
Information Set (HEDIS) quality assessment measure. 
 
A number of strategies are effective in mediating increased 
vaccination including HPV immunization champions,9 provider assessment 
and feedback,10,11 reminders to cue provider treatment and prevention 
behaviors,11,12 provider skills training to improve HPV vaccination message 
delivery and overcome patient (parent)  hesitancy,13 reminders to initiate 
HPV vaccination and return to complete the vaccine series,11,14 and patient 
education and skills training programs.11,13,15 System-level strategies have 
been demonstrated effective because they triangulate approaches at 
various levels (organizational, provider, and patient).11,16,17  
 
Vollrath et al. found that multicomponent interventions have a synergistic 
effect that increases provider vaccine support, improves parents’ attitudes 
about the vaccine, and increases immunization acceptance.16 The 
Community Guide recommends 2 multicomponent interventions: health 
care system-based interventions and community-based interventions 
implemented in combination.11,18  
 
We present the results of a program to increase HPV vaccination. Funded 
by the Cancer Prevention and Research Institute of Texas (CPRIT), 
UTHealth School of Public Health and Baylor College of Medicine 
investigators developed, implemented, and evaluated a multicomponent 
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program that used evidence-based strategies to increase HPV vaccination 




Setting and Population  
 
The Adolescent Vaccination Program (AVP) was conducted from March 
2016 through March 2019 within Texas Children’s Pediatrics (TCP), a 
network of 51 clinics located in the greater Houston area. TCP clinics are 
located in 5 counties--Harris, Galveston, Fort Bend, Montgomery, and 
Brazoria--and serve more than 100,000 children and adolescents ages 11-
17 years, approximately 30% of the pediatric population in the area. Six of 
the clinics are part of TCP’s Community Cares Program, which provides 
care to children regardless of the family’s financial situation or health 
insurance coverage.  
 
At the time of the project, there were 249 physicians and 23 nurse 
practitioners, in addition to other clinical staff. Epic is the medical record 
system used in all TCP clinics. MyChart is the patient portal used to access 
a child’s medical records online, request appointments, receive test results, 
or communicate with the child’s physician. Our target populations were the 
clinic network, healthcare providers (ie, physicians, nurses, other clinic 
staff), and male and female patients ages 11-17 years and their parents 
who attended 1 of the 51 TCP clinics in the network.  
 
Evaluation Question  
 
Does a multicomponent program embedded in a healthcare system and 
delivered to healthcare providers and parents increase HPV vaccination 




For over a year preceding the funded project, we collaborated with the 
medical and professional staff at TCP to identify ways to improve initiation 
of HPV vaccination. The medical director made increasing HPV vaccination 
a goal for the network and worked with us to arrange 6 focus groups at 
clinics that represented the geographic and patient diversity of the TCP 
population. The purpose of the focus groups was to understand attitudes 
and practices regarding HPV vaccination from provider and staff 
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perspectives and to assess receptivity to the program. A total of 78 staff 
including physicians, physicians’ assistants, nurse practitioners, medical 
assistants, and practice managers attended one of the focus groups. 
Meetings were recorded, and topics discussed were summarized by theme 
across the 6 clinics. We used information from the focus groups and our 
meetings with the medical director to select evidence-based strategies that 
were feasible to implement and sustainable within the TCP network. All 6 
clinics agreed to serve as a Stakeholder Advisory Committee (SAC) 
throughout the project. Once funded, we met biweekly with the medical 
director and other TCP staff to discuss progress and identify ways to 
improve implementation of the program. 
 
The program contained a suite of strategies to mediate increased 
vaccination comprising: 1) HPV immunization champions, 2) provider 
assessment and feedback (A&F), 3) continuing medical/nursing education 
(CME/CNE), 4) provider reminders, and 5) tailored patient (parent) 
reminders. Between August 2015 and March 2016 we pilot tested the 
program components in the 6 advisory clinics and made refinements based 
on stakeholder input before rolling them out to the other clinics in March 
2016. The CME/CNE described HPV-associated disease burden, the 
rationale and scientific evidence behind HPV recommendations as well as 
describing proven effective strategies to increase HPV vaccination rates at 
individual, clinic and system levels. It also focused on how principles of 
medical ethics applied to HPV vaccination and employed real-life case 
vignettes to enhance provider communication skills and confidence around 
difficult HPV vaccine discussions. In addition, the medical director 
introduced the project at regional meetings, and he used his monthly 
electronic newsletter to announce the rollout of the project components and 
to encourage all staff to engage in the program. Figure 1 describes the 
components of the AVP. We used a systematic process, Intervention 
Mapping, to develop each of the strategies.20 A detailed description of the 




We used a single group pre/post design with an external comparison group.  
Our primary outcome was initiation of the HPV vaccine among 11- to17-
year-olds based on the electronic health record (EHR) and measured as a 
binary variable (yes/no). We defined initiation as at least 1 dose of the HPV 
vaccine. We calculated monthly, quarterly, and annual rates of HPV vaccine 
initiation for each physician’s patients and clinic in the network and for the 
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entire network. We examined initiation over time in relation to the 
introduction of each of our evidence-based strategies. Our comparison 
group was data for Texas from the National Immunization Survey (NIS)-
Teen for the years 2014 through 2018. The age group reported by NIS-Teen 
was 13-17 years so we used that age group as our comparison with TCP in 
order to examine secular trends.  
 
We used interrupted time series analysis (ITSA)21,22 to measure the change 
in HPV vaccine initiation beginning with the introduction of assessment and 
feedback in March 2016. Other strategies were rolled out through 
September 2017. We continued to implement all strategies through the end 
of the project in March 2019. Beginning with January 2013, we had 38 
months of data prior to introducing the first strategy in month 39, and 37 
months of data on or after that date. An overall model of the network 
measured the change in HPV vaccine initiation before and after the 
introduction of the program. We also compared each clinic’s experience 
with that of all other clinics in the network.  
 











Of the 108,734 patients who visited the clinic during the 3 years of our 
program, 49.4% were female, and 24.2% identified as Hispanic, 13.7% as 
African American, 45.2% as non-Hispanic white, 5.2% as other, and 11.8% 
had missing information. Approximately 80% of families had commercial 
insurance, 13.7% had Medicaid/Medicare, 3.7% had CHIP or Tricare, and 
2.1% had no insurance or were missing information. Most patients preferred 
English (93.3%), 4.7% preferred Spanish, 3.6% spoke another language, 
and 2.1% had missing information.  
 
We examined patterns of initiation for the following factors measured from 
the EHR: patient age, sex, race/ethnicity, and type of insurance. There was 
no missing information for age or sex. For race/ethnicity 11.8% were 
missing information; for insurance, 2.4% were missing information. 
 
We developed 2 online surveys, 1 for TCP physicians and another for 
clinical staff and managers, to assess system- and provider-level factors  
that may influence HPV vaccination practices. Physicians were surveyed in 
July-August 2015 and in January-February 2019. The survey measured 
organizational and patient barriers encountered when vaccinating 
adolescents. Variables on the surveys included previously tested items and 
scales shown to be associated with HPV vaccination practices as well as 
factors identified during our clinic focus groups. The medical director and 
physicians on our SAC reviewed the survey, and we incorporated their 
feedback. The evaluation team at UTHealth emailed physicians and other 
staff a link to the online survey, which took approximately 30 minutes to 
complete; those completing a survey received an electronic gift card from 
UTHealth. We administered the physician survey to all 227 TCP physicians, 
and 130 physicians completed it (57.3% response rate). For the clinic 
survey, we sent an electronic link to 50 practice managers and 423 
advanced practice providers and other clinical staff, and we received 
completed surveys from 45 practice managers (90% response rate) and 
375 advanced practice providers and clinical staff (88.7% response rate). 
Responses were well distributed across clinics with response rates ranging 
from 22% to 100%. Initial results of the physician survey are reported 
elsewhere.23 
 
We compared TCP rates with data for Texas and Houston from the NIS-
Teen for the years 2014 through 2018 (Figure 2). Because the age group 
reported for NIS-Teen was 13-17 years, we used that age group for 
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comparison with TCP. At baseline, initiation rates for TCP and Houston 
were approximately 60%; however, compared with Houston, TCP rates 
increased 28% vs 20.7% for Houston from baseline to year 3 (Figure 2).  
 
Figure 2. HPV Vaccine Initiation Comparing TCP, Texas, and City of 




*Data for Texas and City of Houston are from NIS-Teen survey years 2014-2018. NIS 
Teen data are only available for ages 13-17; therefore, TCP data are for the same ages. 
 
September 2014 through August 2015 was the baseline year for the AVP 
program. Figure 3 shows the timeline for the introduction of our strategies 
in relation to HPV vaccine initiation rates for the overall clinic network for 
year 1 through the end of the program for ages 11-17. Initiation rates 
increased annually from September 2015 through the end of March 2019 
(Table 1 and Figure 3). ITSA analysis of the network data over 75 months 
showed an increase in HPV vaccination initiation of 0.396% per month from 
the introduction of the program at month 39 (Figure 4). Average individual 
clinic improvement was 0.37% per month ranging from -0.04% to 0.68% 
from the 39th month through March 2019. Data from 4 clinics were not 
included because they did not have data for all 75 months for the ITSA 
analysis. Initiation rates at baseline were slightly higher in the 6 advisory 
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Table 1. Patient Demographics and HPV Vaccine Initiation by Year, Ages 11-17 
 
   HPV Vaccine Initiation 






Population N % N % N % N % N % 
Ages 11-17 111,126  100,472 56.4 107,505 64.4 115,225 72.6 121,301 76.8 123,861 77.4 
   Ages 11-12 40,453 36.4 37,109 45.9 39,252 56.4 41,749 67.0 43,701 71.0 44,611 70.8 
   Ages 13-17 70,673 63.6 63,363 62.5 68,253 69.0 73,476 75.8 77,600 80.0 79,250 81.0 
Female 54,975 49.5 49,713 58.9 53,136 65.7 56,877 73.0 60,175 76.6 61,419 77.3 
Male 56,151 50.5 50,759 53.9 54,369 63.1 58,348 72.2 61,126 77.0 62,442 77.4 
Non-Hispanic White 49,387 44.4 46,807 52.0 48,568 59.7 50,765 67.8 51,408 72.3 51,947 72.7 
Non-Hispanic AfAm 15,345 13.8 13,576 63.4 14,767 71.1 15,792 78.5 17,246 81.2 17,852 81.7 
Hispanic 27,534 24.8 23,302 63.7 25,743 71.5 29,014 78.7 32,077 81.8 33,109 82.3 
Other or Unknown 
Ethnicity 18,860 17.0 16,787 53.0 18,427 61.4 19,654 71.4 20,570 76.5 21,106 77.4 
Commercial Insurance 89,220 80.3 81,094 54.3 86,331 62.7 92,676 71.2 96,779 75.6 91,984 75.7 
Medicare/Medicaid 18,793 16.9 16,289 68.2 18,253 74.1 19,425 80.8 21,206 83.8 28,464 83.7 
Other Insurance 872 0.8 695 54.2 805 63.7 923 70.2 1,066 73.2 1,113 73.1 
None 2,240 2.0 2,394 47.8 2,116 51.3 2,201 59.2 2,250 63.1 2,300 65.7 
English Language 103,442 93.1 94,152 55.7 100,407 63.7 107,052 71.9 112,156 76.1 114,200 76.7 
Spanish Language 5,529 5.0 4,294 73.7 4,968 78.7 5,941 85.4 6,912 86.9 7,271 87.2 
Other or Unknown 
Language 1,583 1.4 1,483 55.9 1,545 64.2 1,622 72.9 1,680 78.8 1,821 79.2 
 
Baseline = 9/1/2014-8/31/2015 
Year 1 = 9/1/2015-8/31/2016 
Year 2 = 9/1/2016-8/31/2017 
Year 3 = 9/1/2017-8/31/2018 
End = 9/1/2018-2/28/2019
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Figure 3. % HPV Vaccine Initiation for Patients Ages 11-17 by Year and Round of AVP Strategies 
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Data for the 11-12 year age group, the target age group for initiating the 
vaccine, showed a greater percentage increase (54.2%) compared with the 
13- to 17-year-olds (29.6%) (Table 1 and Figure 5). Rates of initiation were 
higher for females than males at baseline and year 1, but were similar in 
years 2-4 (Table 1 and Figure 6). Although patterns were generally similar 
for all racial/ethnic groups, Hispanics and African-Americans had the 
highest initiation rates in all years while non-Hispanic whites had the lowest 
rates (Table 1 and Figure 7). Families without insurance had the lowest 
rates while those with Medicaid/Medicare had the highest rates (Table 1 
and Figure 8). Those with commercial or other types of insurance had rates 
that were intermediate between those with Medicaid/Medicare and those 
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Discussion 
 
HPV vaccination prevents most cervical, oropharynx, anus, penis, vulva, 
and vagina cancers. Although vaccination rates are slowly increasing, they 
do not yet meet the American Cancer Society’s goal to have 80% of 
adolescents up to date before their 13th birthday by 2026. 24 The AVP was 
developed to enable providers to increase their rate of HPV vaccination. 
The program consists of the successive rollout of 5 evidence-based 
strategies. It was evaluated in a large clinic network in the Houston area 
that serves an estimated 30% of the pediatric population in a 5-county 
area.19 During the 3-year period that the program was in place, initiation of 
the HPV vaccine increased from approximately 50% to 80% in the areas 
served by TCP.   
  
Consistent with other studies,25-27 the prevalence of HPV initiation was 
slightly higher in females than males in the early years of the project but 
rates coalesced by the end of the project. Hispanics and African Americans 
had higher initiation rates in all years of the project compared with non-
Hispanic whites. Families without insurance had the lowest rates while 
those with Medicaid/Medicare had the highest.25  
 
An important strength of our project was that we worked closely with the 
clinic leadership for over a year prior to receiving funding.  This lead time 
was crucial for understanding the system and establishing trusting 
relationships. For example, the medical director facilitated communication 
with the 51 clinics by using his monthly newsletter to introduce the stage of 
the project. We also were permitted to use internal office mail to distribute 
materials related to our strategies, eg, assessment and feedback reports. 
Another strength of our project was clinic leadership support to develop a 
vaccine registry in conjunction with the network IT department to enable 
more accurate records of vaccination status. This was vital for effectively 
targeted patient reminders. Further, clinic leadership facilitated the inclusion 
of branched chain decision algorithms within the Epic EHR enabling tailored 
reminders to providers on patient vaccine eligibility and responsiveness to 
changes that occurred to the guidelines during the project, eg, change in 
the dose for adolescents 15 years or younger from 3 to 2.   
 
A limitation of the project was the pre/post design. Without a comparison 
group from the same population, we could not directly rule out alternative 
hypotheses, particularly secular trends. We used rates for Houston from 
NIS-Teen as a proxy, and we observed a secular trend in both TCP and 
12
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NIS-Teen data; however, the NIS-Teen Houston data showed a more 
gradual increase compared with TCP data, suggesting that our program 
was effective at increasing HPV vaccination beyond secular trends. In 
addition to secular trends, there were other activities that promoted and 
encouraged HPV vaccination both in and outside the clinic network 
including the Texas HPV Coalition, a group of organizations with the goal 
of increasing HPV vaccination in Texas (https://texashpvcoalition.org). 
Because TCP patients constitute a sizable proportion of NIS-Teen 
estimates, it is possible that estimates of initiation for Houston from NIS-
Teen are overestimated. Finally, the demographics of TCP and Houston 
differ. According to 2018 interim census estimates, Houston is 25% non-
Hispanic white, 51.6% commercially insured, and 51.2% English language 
preference compared with TCP, which is 44% non-Hispanic white, 80% 
commercially insured, and over 90% English language preference.  
 
The AVP is a promising program for sequenced rollout of evidence-based 
strategies to increase HPV vaccination initiation in a clinic setting. The AVP 
was effective at increasing initiation of the HPV vaccine series among male 
and female adolescent patients. The program was designed as sequential 
but overlapping rollout of individual components, limiting our ability to test 
the effectiveness of each component (eg, CME/CNE). It is possible that 
there was a synergistic relationship between components because 
improving knowledge and communication skills are likely a prerequisite to a 
provider’s ability to improve suboptimal vaccination rates, as highlighted in 
audit and feedback reports.16 Further, despite the time pressures on 
physicians, we demonstrated willingness to engage in physician-targeted 
interventions (CME and A&F). In a survey of physicians and clinic staff at 
the end of the program, over 80% agreed or strongly agreed with the 
statement “willing to use new programs”. We continued to monitor 
vaccination rates for a year beyond implementation of the program, and 
rates did not decline, suggesting that some of the strategies were sustained.  
 
While demonstrated effective in this project, the potential for the AVP to be 
adopted and implemented in other clinical networks remains to be 
determined. Because the demographic composition of TCP and Houston 
differ, generalization of our results should be done cautiously. We are in the 
process of replicating the AVP in a smaller network of clinics with a different 
population in San Antonio, Texas (PP180089). We also are developing a 
dissemination plan whereby clinics may access a web-based program that 
includes a stepped guide, tools, and resources to guide implementation of 
the AVP, tailored to their clinic system’s needs (PP190041). Critical in such 
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a plan is that clinics have the capacity to readily onboard the AVP evidence-
based strategies on their own, beyond the infrastructure support of a funded 
evaluation trial. Finally, in another CPRIT project, we developed and tested 
an app for parents (RP150014). The app provides information to dispel 
myths about HPV and the vaccine and to schedule an appointment for their 
child.    
14
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